Davalintide (AC2307), a novel amylin-mimetic peptide: enhanced pharmacological properties over native amylin to reduce food intake and body weight
Christine M. Mack, David G. Parkes(Amplyx Pharmaceuticals (United States)), Richard Pittner, Aung N. Lwin, James L. Trevaskis, Kevin D. Laugero(Agricultural Research Service), Jennifer Athanacio(Amplyx Pharmaceuticals (United States)), Victoria F. Turek, John Herich(Amplyx Pharmaceuticals (United States)), Sean H. Adams(Western Human Nutrition Research Center), Carolyn M. Jodka, James R. Paterniti(Unknown), Calvin Vu, Jonathan D. Roth(Rutgers, The State University of New Jersey), Soumitra S. Ghosh(Amplyx Pharmaceuticals (United States)), Michael R. Hanley(University of Virginia Health System), Julie Wilson, Porsha Smith, B L Roland, Bronislava Gedulin(Amplyx Pharmaceuticals (United States)), Carlos José Soares(Universidade Federal de Uberlândia)
Cited by 112
Related Papers
Leptin responsiveness restored by amylin agonism in diet-induced obesity: Evidence from nonclinical and clinical studies
|Proceedings of the National Academy of Sciences|2008|433
Amylin: Pharmacology, Physiology, and Clinical Potential
|Pharmacological Reviews|2015|395
Endocrine and Metabolic Effects of Consuming Fructose- and Glucose-Sweetened Beverages with Meals in Obese Men and Women: Influence of Insulin Resistance on Plasma Triglyceride Responses
|The Journal of Clinical Endocrinology & Metabolism|2009|300
Diet-induced mouse model of fatty liver disease and nonalcoholic steatohepatitis reflecting clinical disease progression and methods of assessment
|American Journal of Physiology-Gastrointestinal and Liver Physiology|2013|294
Glucagon-like peptide-1 receptor agonism improves metabolic, biochemical, and histopathological indices of nonalcoholic steatohepatitis in mice
|American Journal of Physiology-Gastrointestinal and Liver Physiology|2012|278